Does the Micra leadless VVI pacemaker reduce reinterventions and chronic complications compared to transvenous VVI pacing in US Medicare patients?
In a real-world Medicare population, leadless VVI pacing significantly reduced reinterventions and chronic complications compared to transvenous pacing at 2 years, without affecting mortality.
In a real-world study of US Medicare patients, the Micra leadless VVI pacemaker was associated with a 38% lower adjusted rate of reinterventions and a 31% lower adjusted rate of chronic complications compared with transvenous VVI pacing. There was no difference in adjusted all-cause mortality at 2 years.
El‐Chami et al. (Thu,) studied this question.